iCAD (ICAD) Q4 2024 earnings summary

Executive summary

• Q4 2024 revenue reached $5.4 million, up 14% year-over-year, with full year revenue at $19.6 million and ARR of $9.8 million, reflecting strong SaaS transition and AI adoption in healthcare.

• ProFound Detection Version 4.0, the most advanced AI solution, received FDA clearance and demonstrated significant improvements in cancer detection and workflow efficiency.

• Closed 106 deals in Q4 (54 perpetual, 33 subscription, 19 cloud), with 382 total deals in 2024, including 42 ProFound Cloud deals, and expanded globally through new partnerships and distribution agreements.

• SaaS and cloud adoption accelerated, with cloud deals increasing each quarter and ARR growing 11% year-over-year.

• SaaS transition is expected to create short-term headwinds for GAAP revenue but will drive long-term financial predictability and high-margin recurring revenue.

Financial highlights

• Q4 2024 revenue was $5.4 million, up 14% year-over-year; full year revenue was $19.6 million, up from $17.3 million in 2023.

• Q4 product revenue grew 24% to $3.7 million; full year product revenue was $12.5 million, up from $9.9 million.

• Q4 service revenue was $1.7 million, flat year-over-year; full year service revenue was $7.1 million, down from $7.4 million.

• Gross profit margin for Q4 was 86%, down from 91% last year due to a one-time benefit in 2023 and cloud product amortization; full-year gross margin was 85%.

• Q4 GAAP net loss from continuing operations was $0.9 million ($0.03 per share); full year net loss was $5.6 million ($0.21 per share), improved from $7 million in 2023.

Outlook and guidance

• SaaS transition expected to take up to three years, with 2025 marking a significant phase as cloud adoption accelerates.

• Short-term headwinds to GAAP revenue and cash flow anticipated, but long-term benefits include higher predictability and margins.

• Sufficient cash resources ($17.2 million as of year-end) to fund planned operations for at least the next 12 months.

• Continued focus on ARR growth, SaaS expansion, and global regulatory approvals.